Asthma is a global health problem that affects over 300,000 British Columbians. It is a group of diseases that is caused by
inflammation of the lung airways, which leads to airway narrowing and breathing difficulties. Inflammation is the body’s normal
response to perceived threats, such as bacteria and viruses. In asthma, the inflammatory response in the lungs is over-sensitized,
disrupting normal lung function. Thus, there is an urgent clinical need to find effective therapies for asthma.
Granzyme K belongs to the Granzyme protein family that plays key roles in many inflammation-associated diseases. Although
granzyme K has been found at elevated levels in the lungs of asthma patients, its role in allergic asthma is widely unexplored.
We propose to examine the role that Granzyme K plays in asthma in established experimental models. Specifically, we will examine
localization of Granzyme K in the lungs and the cells responsible for its production. We will also evaluate how Granzyme K
contributes to the onset and progression of allergic asthma. Our findings will improve our understanding of Granzyme K and the
role it plays in asthmatic lungs. Importantly, this study will evaluate Granzyme K as a candidate drug target for asthma.